A synbiotic composition and its use

Abstract

The present invention relates to a synbiotic composition comprising probiotics and dietary fiber, wherein the probiotics are selected from Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) BPB22; dietary fiber is derived from one or more of white lentils, goji berries, red dates, bitter melon, lotus seeds, buckwheat, Chinese yam, oats, corn silk, and coix seed. The synbiotic composition of the present invention can significantly improve symptoms of a high-fat diet, including excessive caloric intake, weight gain, fat accumulation, muscle loss, impaired insulin sensitivity, impaired glucose tolerance, insulin resistance, and decreased fecal short-chain fatty acid levels.

Description

Technical Field

[0001] The present invention belongs to the technical fields of compositions, microorganisms, metabolic disease treatment and nutrition, and in particular relates to a synbiotic composition for improving glucose and lipid metabolism and its use, which has important specific effects on intestinal health and the treatment of metabolic diseases such as abnormal glucose and lipid metabolism. Background Art

[0002] In recent years, people's lifestyles have undergone dramatic changes, shifting from a traditional plant-based diet to a Western diet dominated by animal products. This has led to a significant increase in the incidence of chronic metabolic diseases such as obesity and type 2 diabetes. A high-fat diet leads to an imbalance between nutrient intake and expenditure, which in turn causes glucose and lipid metabolism disorders. Key symptoms include fat accumulation, impaired glucose tolerance, and insulin resistance, ultimately leading to obesity, diabetes, and a host of complications, placing a significant medical and economic burden on society.

[0003] Studies have shown that intestinal dysbiosis is closely related to chronic metabolic diseases, and dietary nutrition can affect the structure and metabolites of the intestinal flora. Intestinal dysbiosis caused by a high-fat diet leads to an increase in opportunistic pathogens in the intestine and a decrease in short-chain fatty acid-producing bacteria, which in turn affects the intestinal barrier and allows harmful metabolites to enter the human circulatory system, leading to systemic chronic inflammation and further metabolic diseases. High-fiber dietary intervention can enrich short-chain fatty acid-producing bacteria, which acidify the intestine by producing metabolites such as acetate and butyrate, inhibiting opportunistic pathogens and thus improving type 2 diabetes.

[0004] Synbiotics are a mixture of active microorganisms and substrates that can be selectively utilized by microorganisms. They are not just a simple superposition of probiotics and prebiotics, but place more emphasis on the selective support of substrates for active microorganisms. Synbiotics can specifically supplement and support strains that are closely related to the improvement of host disease phenotypes, such as the growth of short-chain fatty acid-producing strains in the intestine, thereby more effectively affecting the intestinal environment and repairing intestinal flora imbalance, and have more clinical application prospects than the use of probiotics or prebiotics alone. Currently, there are few synbiotics used to improve abnormal glucose and lipid metabolism, and most of the compositions use simple substrates with low molecular weight, such as inulin, oligosaccharides, etc., which have limited selective support for active microorganisms. Therefore, it is of great significance to develop synbiotic compositions that have selective support for active microorganisms and can improve abnormal glucose and lipid metabolism. Summary of the Invention

[0005] In response to the problems existing in the prior art, the present invention provides a synbiotic composition that can provide a high-molecular-weight fiber substrate to specifically support the growth of short-chain fatty acid-producing strains and the production of butyrate, significantly improving the abnormal glucose and lipid metabolism caused by a high-fat diet.

[0006] In order to solve the above technical problems, the synbiotic composition provided by the present invention includes Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale )BPB22 and dietary fiber.

[0007] Especially Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale )BPB22 and high molecular weight coix seed soluble dietary fiber YRS.

[0008] Among them, Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ) HYL95 strain was deposited in China Center for Type Culture Collection (CCTCC) with the deposit number CCTCC NO: M 2025538 and the deposit date March 20, 2025. Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20 strain was deposited in China Center for Type Culture Collection (CCTCC) with the deposit number CCTCC NO: M 2025537 and the deposit date March 20, 2025. Eubacterium rectum ( Eubacterium rectale ) The BPB22 strain was deposited in the China Center for Type Culture Collection (CCTCC) with the deposit number CCTCC NO: M 20232177 and the deposit date on November 10, 2023.

[0009] In order to solve the above technical problems, the specific technical solutions adopted by the present invention are as follows:

[0010] In a first aspect of the present invention, a synbiotic composition is provided, comprising probiotics and dietary fiber, wherein the probiotics are selected from Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) One or more of BPB22; the dietary fiber comes from one or more of white lentils, wolfberries, red dates, bitter melon, lotus seeds, buckwheat, yam, oats, corn silk, and coix seed.

[0011] In some embodiments, the dietary fiber is soluble dietary fiber.

[0012] In some specific embodiments, the dietary fiber comes from one or more of white lentils, lotus seeds, and coix seeds.

[0013] In some embodiments, the probiotic is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii (Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) BPB22 three kinds of probiotics, and the dietary fiber is coix seed soluble dietary fiber.

[0014] In some embodiments, the ratio of the probiotics to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale The dosage ratio of BPB22 and high molecular weight coix seed soluble dietary fiber ranged from (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (50-150) g / L.

[0015] In some embodiments, the ratio of the probiotics to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) The dosage ratio of BPB22 and high molecular weight coix seed soluble dietary fiber was 5×10 8 CFU / mL: 5×10 8 CFU / mL: 5×10 8 CFU / mL: 100g / L.

[0016] In the second aspect of the present invention, the synbiotic composition as described above is used in the preparation of a drug for promoting the production of short-chain fatty acids in the intestine.

[0017] Use of the synbiotic composition as described above in the preparation of a drug for promoting intestinal butyrate production.

[0018] Use of the synbiotic composition as described above in preparing a drug for controlling postprandial blood sugar and treating insulin resistance.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] 1. The synbiotic composition provided by the present invention can provide a high molecular weight dietary fiber substrate to specifically support butyrate production by short-chain fatty acid producing strains.

[0021] 2. The synbiotic composition provided by the present invention can significantly improve symptoms such as excessive calorie intake, weight gain, fat accumulation, muscle loss, impaired insulin sensitivity, impaired glucose tolerance, insulin resistance, and reduced fecal short-chain fatty acid content caused by a high-fat diet.

[0022] The concept and technical effects of the present invention will be further described below with reference to the accompanying drawings to fully understand the purpose, features and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 A in the formula is the extraction process of dietary fiber. Figure 1 The B in it refers to the forms and names of 20 kinds of dietary fiber.

[0024] Figure 2 A in the equation is the pH and acetic acid and butyric acid yields of mixed fermentation of different fiber substrates by functional strains. Figure 2 B in the figure is the description of the strains used in the experiment and the differential growth of different strains in culture media with different substrates.

[0025] Figure 3 This is an experimental design to intervene in high-fat diet mice with synthetic microbial composition.

[0026] Figure 4 The weight growth rate (A), food intake (B), energy intake (C), the proportion of four types of white fat and total white fat in body weight (D), the proportion of vastus lateralis muscle in body weight (E), the average area of ​​epididymal adipocytes and representative HE-stained sections (F), the liver non-alcoholic fatty liver disease (NAFLD) activity score and representative HE-stained sections (G) of the mice in each group.

[0027] Figure 5 The ITT blood glucose curve (A), area under the ITT blood glucose curve (B), OGTT blood glucose curve (C), area under the OGTT blood glucose curve (D), insulin curve (E), area under the insulin curve (F), homeostasis model of insulin resistance HOMA-IR index (G), and the product of the area under the OGTT blood glucose curve and the area under the insulin curve from 0 to 60 minutes (H) of each group of mice.

[0028] The contents of total short-chain fatty acids (A), acetic acid (B), propionic acid (C), butyric acid (D), isobutyric acid (E), valeric acid (F), and isovaleric acid (G) in the feces of mice in each group were respectively. DETAILED DESCRIPTION

[0029] To provide a more detailed understanding of the technical content, features, and effects of the present invention, the technical solutions of the present invention are now described in further detail with reference to the accompanying drawings and specific embodiments. The embodiments described are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other implementations obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0030] Example 1 Extraction of fibrous substrate

[0031] According to the method of GB5009.88-2014 "National Food Safety Standard Determination of Dietary Fiber in Food", an experimental process for extracting and separating soluble and insoluble dietary fiber components from natural plant materials was designed, as shown in A in Figure 1.

[0032] The insoluble dietary fiber and high molecular weight soluble dietary fiber of 10 natural raw materials, including white lentil, wolfberry, red date, bitter melon, lotus seed, buckwheat, yam, oat, corn silk and coix seed, were extracted. The morphology and naming of 20 different fibers are as follows: Figure 6 As shown in Figure B. The raw flours of each raw material were ground and dissolved in 0.05 M MES-TRIS buffer at a material-liquid ratio of 1:10. The starch, protein, and fat in the raw flours were then enzymatically digested into various small molecules by using a heat-stable α-amylase at 95°C for 1 hour, alkaline protease at 60°C, pH 7.5 for 30 minutes, glucosidase at 60°C, pH 4.5 for 30 minutes, and pancreatin at 37°C, pH 7 for 1 hour. The enzymes were then inactivated by boiling at 100°C for 10 minutes. The precipitate from the enzyme aqueous extract was collected by centrifugation, washed with ultrapure water, freeze-dried, and ground to obtain the insoluble dietary fiber fraction. The supernatant from the enzyme aqueous extract was collected, concentrated, and then precipitated with 4 volumes of ethanol to extract the soluble dietary fiber. The supernatant was discarded, and the precipitate was washed with ethanol and reconstituted with hot water. Add Sevage reagent at a volume ratio of 1:4, vortex to mix, and centrifuge. Collect the supernatant and discard the protein precipitate. Repeat the Sevage reagent treatment multiple times until no milky white precipitate is visible. Place the supernatant into a dialysis bag with a molecular weight cutoff of 7000 Da and dialyze it three times, replacing the ultrapure water every 12 hours. The dialysate retained in the bag is then freeze-dried and ground to obtain high-molecular-weight soluble dietary fiber.

[0033] Example 2 In vitro screening of different fiber substrates for the ability of functional strains to support butyrate production

[0034] YCFA medium without additional carbon source was used as negative control (NC), YCFA medium with additional glucose at a final concentration of 0.5% was used as positive control (GLU), and YCFA medium with additional 20 different fiber substrates at a final concentration of 0.5% was used as different fermentation media, named as follows: Figure 1 The experiment was carried out as follows Figure 1 The five active functional strains producing short-chain fatty acids isolated from human feces shown in B were first fermented in vitro on 20 different fiber substrates to screen out fiber substrates that support the functional strains to produce butyrate.

[0035] Each active strain was inoculated into YCFAG medium at a 2% ratio and incubated anaerobically at 37°C for 36 hours for activation. The strains were then transferred to YCFAG medium at a 2% ratio and incubated anaerobically at 37°C for 24 hours for expansion. After expansion, the cells were harvested by centrifugation at 7000g for 10 minutes, washed with PBS buffer containing 0.1% cysteine, and centrifuged again to remove residual culture medium. The cells were resuspended in YCFA medium and diluted to an OD600 of approximately 1.0. The five functional strains were mixed in equal proportions and inoculated into each of the 22 aforementioned culture media at a 2% ratio. The cells were mixed by inversion and incubated anaerobically at 37°C for 48 hours.

[0036] After 48 hours of fermentation, centrifuge at 10,000 g for 10 minutes, collect the supernatant, and measure the pH using the phenol red method using 20 μL of the supernatant. Acidify 200 μL of the supernatant with 100 μL of 50% sulfuric acid to release the short-chain fatty acids in molecular form. Add 400 μL of ether, vortex to mix, and extract the short-chain fatty acids using ether. Let the mixture stand for 2 minutes, then centrifuge at 14,000 g for 5 minutes at 4°C. The upper ether phase is collected and analyzed by flow cytometer.

[0037] After determining the retention times of six short-chain fatty acids (SCFAs) (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid), aqueous solutions of the six SCFA standards were prepared using a gradient dilution method at concentrations of 0.0025, 0.005, 0.01, 0.02, and 0.04 μL / mL. These solutions were then acidified, extracted, and analyzed using the same methods as the samples. An Agilent 6890 gas chromatograph (Agilent Technologies, USA) was used for detection using a polar HP-FFAP column (0.25 mm × 0.25 mm × 30 μm, Agilent Technologies, USA). Helium was used as the carrier gas. The column temperature was initially set at 140°C for 6 min and then increased to 250°C at a rate of 25°C / min for 2 min. The inlet temperature was 250°C, and the detector temperature was 280°C. The SCFA content in the fermentation broth was calculated based on a calibration curve generated using the standards. All manual operations were performed on ice.

[0038] The results of supernatant pH and acetic acid and butyric acid production are as follows Figure 2 As shown in Figure A, when white lentil soluble fiber BBDS, lotus seed soluble fiber LZS, and coix seed soluble fiber YRS were used as substrates, the butyrate produced by the mixed bacterial community fermented the fibers more than that produced by glucose fermentation. This indicates that compared to glucose, these three fiber substrates are more effective in promoting the growth and production of butyrate-producing bacteria in the mixed bacterial community, with coix seed soluble fiber YRS showing the strongest support for butyrate production by the functional strains.

[0039] Example 3 Evaluation of the specific supporting ability of coix seed soluble fiber on the growth of functional strains

[0040] YCFA medium without additional carbon source was used as blank control (NC), YCFA medium supplemented with glucose (GLU) or inulin (INU) at a final concentration of 0.5% was used as positive control, and YCFA medium supplemented with coix seed soluble fiber substrate at a final concentration of 0.5% was used as fermentation medium. Figure 2 As shown in Figure B, four opportunistic pathogens and five short-chain fatty acid-producing functional strains isolated from human feces were fermented in vitro on a coix seed soluble fiber substrate to evaluate the ability of the fiber to specifically support the functional strains.

[0041] Each strain was inoculated into the growth medium at a ratio of 2%, and after activation by anaerobically culturing at 37°C for 36 hours, it was transferred to the growth medium at a ratio of 2%, and then culturing at 37°C for 24 hours for expansion culture. After the strain was expanded, the bacteria were collected by centrifugation at 7000g for 10 minutes, washed with PBS buffer containing 0.1% cysteine, and centrifuged again to remove the residual culture medium. The bacteria were resuspended in YCFA medium and diluted to an OD600 of about 1.0. Each bacteria was transferred to 4 culture media at a ratio of 2%, and the OD600 value was measured after anaerobic culture for 48 hours. The results are as follows Figure 2 As shown in Figure B, all strains can grow using both glucose and inulin, with their ability to grow in inulin being slightly weaker than in glucose. However, only five active functional strains can grow using coix seed soluble fiber, while four opportunistic pathogens cannot grow in the coix seed soluble fiber medium. This indicates that coix seed soluble fiber can specifically support the growth of active functional strains.

[0042] Example 4: Synbiotic Composition Improves Glucose and Lipid Metabolism in Mice Fed a High-Fat Diet

[0043] This experiment used 60 8-week-old specific pathogen-free (SPF) male C57BL / 6J mice, which were raised in the SPF barrier of the Shanghai Jiao Tong University Laboratory Animal Center. Figure 2 As shown. After 2 weeks of adaptation, the mice were randomly divided into 6 groups, with 10 mice in each group. Different interventions were gavaged according to the groups, and the mice were free to eat and drink water for 8 weeks. The NC group was fed with a control diet and gavaged with 200uL of phosphate buffered saline (PBS) solution containing 2% skim milk every day. The HFD group was used as a modeling group and was fed with a high-fat diet and gavaged with 200uL of PBS solution containing 2% skim milk every day. The PGC group was used as a positive control group and was fed with a high-fat diet and gavaged with 200uL of PGC synbiotics dissolved in PBS solution every day, which contained 2% skim milk and 10 of each strain of bacteria. 8 PGC (Pendulum Glucose Control) is a synbiotic capsule containing 5 strains and 1 prebiotic, specifically Clostridium beijerinckii ( Figure 3 )WB-STR-0005, Clostridium butyricum ( Clostridium beijerinckii )WB-STR-0006, Akkermansia muciniphila ( Clostridium butyricum Akkermansia )WB-STR-0001, Eubacterium hallii ( muciniphila )WB-STR-0008, Bifidobacterium infantis ( Eubacterium hallii) 100 and chicory inulin. PGC Synbiotics is currently the only synbiotic special medical product that has been clinically proven to be used in clinical practice. It can effectively reduce glycated hemoglobin (A1C) and blood sugar peaks in patients with type 2 diabetes. Group F was fed a high-fat diet and gavage daily with 200uL of PBS solution dissolved in coix seed soluble fiber, containing 2% skim milk and 20mg coix seed soluble fiber YRS. Group S was fed a high-fat diet and gavage daily with 200uL of PBS solution dissolved in a bacterial strain mixture, containing 2% skim milk and 10 each of Bifidobacterium pseudomicrocystis HYL95, Faecalibacterium prausnitzii F20, and Eubacterium rectum BPB22. 8 The FS group was fed a high-fat diet and gavaged daily with 200 μL of a fiber bacterial strain composition dissolved in PBS solution, including 2% skim milk, 20 mg of coix seed soluble fiber YRS, and 10 each of Bifidobacterium pseudocatenulatum HYL95, Faecalibacterium prausnitzii F20, and Eubacterium rectum BPB22. 8 CFU. During the experiment, mouse body weight changes were recorded. An insulin tolerance test (ITT) was performed at week 7 of intervention, and an oral glucose tolerance test (OGTT) was performed at week 8 of intervention. Mice were sacrificed and sampled after the OGTT at week 8. The Biostime PGCs used in this example were purchased from Pendulum Therapeutics, Inc., USA.

[0044] The ITT experiment was performed as follows: mice were fasted for 6 hours after changing their bedding but not depriving them of water. They were weighed before the experiment and given an intraperitoneal injection of insulin at a dose of 0.75 U / kg body weight. Blood was collected from the tail tip vein at 0, 15, 30, 45, 60, and 90 minutes, and blood glucose levels were measured using a glucometer. The OGTT experiment was performed as follows: mice were fasted for 6 hours after changing their bedding but not depriving them of water. They were then gavaged with 25% glucose solution at a dose of 2.0 g / kg body weight. Blood was collected from the tail tip vein at 0, 15, 30, 60, and 120 minutes, and blood glucose levels were measured using a glucometer. Blood was collected from the tail tip at 0, 15, and 60 minutes for insulin measurement. The blood glucose and insulin levels at time zero were defined as fasting blood glucose and fasting insulin. The homeostasis model of insulin resistance (HOMA-IR) index is calculated as fasting blood glucose × fasting insulin / 22.5.

[0045] Determination of Short-Chain Fatty Acids in Mouse Feces: Collect mouse fecal samples on dry ice. Rapidly transfer >150 mg of feces to a screw-cap tube and weigh the sample. Add two volumes of PBS (w / v = 1:2) to the tube and disperse the feces with a toothpick until no solid particles remain. Place the tube in the adapter of the Tissuelysser II and shake at 20 Hz / s for 90 seconds. Centrifuge at 16,000 g for 15 minutes at 4°C. Collect the supernatant and transfer it to a new 1.5 mL EP tube. Filter the fecal extract through a 0.22 µm sterile filter membrane. Determine short-chain fatty acids as in Example 2.

[0046] Experimental result 1: Synbiotic composition FS can improve the weight gain and energy intake of mice induced by high-fat diet. Bifidobacterium infantis AC in the HFD group. The HFD group showed a significantly higher body weight gain and a significantly lower food intake than the NC group. However, due to the higher energy density of the high-fat diet, the HFD group had a significantly higher energy intake than the NC group. The PGC and FS groups both showed a significantly lower body weight gain than the HFD group, but only the FS group had significantly lower food intake and energy intake than the HFD group. There were no significant differences in any of the indicators between the F and S groups and the HFD group.

[0047] Experimental result 2: Synbiotics composition FS can improve fat accumulation and muscle loss in mice caused by high-fat diet. Figure 4 The DG in the HFD group. The four types of white fat, the total white fat percentage, and the average fat cell area of ​​mice in the HFD group were significantly higher than those in the NC group. The non-alcoholic fatty liver disease (NAFLD) activity score of mice in the HFD group was significantly higher than that in the NC group. The liver showed relatively severe fatty degeneration, and the hepatocytes contained a large number of fat vacuoles. The weight of the vastus lateralis muscle of mice in the HFD group was significantly lower than that in the NC group. The total white fat percentage and the average fat cell area of ​​the PGC and FS groups were significantly lower than those in the HFD group. The NAFLD activity score of the FS group was significantly lower than that of the HFD group, and the NAFLD activity score of the PGC group showed a trend of being significantly lower than that of the HFD group. Only the vastus lateralis muscle percentage of mice in the FS group showed a trend of being significantly higher than that of the HFD group, and was significantly higher than that of the PGC group. There were no significant differences in the various indicators of the F and S groups compared with the HFD group.

[0048] Experimental result 3: Synbiotics composition FS can improve the impaired insulin sensitivity caused by high-fat diet, such as Figure 4 AB in the . Fasting blood glucose, ITT blood glucose at each time point, and the area under the ITT blood glucose curve (AUC) in the HFD group were significantly higher than those in the NC group. ITT blood glucose at multiple times and the AUC in the PGC and FS groups were significantly lower than those in the HFD group. No significant differences were found in these indicators between the F and S groups and the HFD group.

[0049] Experimental result 4: Synbiotic composition FS can improve impaired glucose tolerance and insulin resistance in mice induced by high-fat diet. Figure 5 The HFD group showed significantly higher fasting blood glucose, blood glucose at each time point during the OGTT, blood glucose area under the curve (AUC), fasting insulin, insulin at each time point, insulin AUC, the HOMA-IR index (indicating insulin resistance), and the product of the AUC for the 0-60 minute OGTT blood glucose and AUC for insulin compared to the NC group. The PGC and FS groups showed a trend toward significantly lower AUCs for the OGTT and HOMA-IR than the HFD group. Only the FS group showed a significantly lower AUC for the 0-60 minute OGTT and AUC for insulin compared to the HFD and PGC groups, and only the FS group showed a trend toward significantly lower AUC for insulin compared to the HFD and PGC groups. No significant differences were observed between the F and S groups and the HFD group in these indicators.

[0050] Experimental result 5: Synbiotics composition FS can improve the decrease in short-chain fatty acid content in mouse feces caused by high-fat diet, such as Figure 5 Figure 6 . Compared with the NC group, the content of total short-chain fatty acids in the feces of mice in the HFD group was significantly decreased, among which the contents of acetic acid, propionic acid and valeric acid were significantly decreased, and the contents of butyric acid, isobutyric acid and isovaleric acid showed a significant downward trend. The intervention of the PGC and FS groups significantly increased the contents of acetic acid, valeric acid and total short-chain fatty acids in the feces of mice. Only the intervention of the FS group significantly increased the butyric acid content in the feces of mice. There was no significant difference in the indicators of the F and S groups and the HFD group.

[0051] The preferred embodiments of the present invention have been described in detail above. It should be understood that numerous modifications and variations based on the concepts of the present invention are possible without inventive effort by those skilled in the art. Therefore, any technical solution that can be derived by one skilled in the art through logical analysis, reasoning, or limited experimentation based on the concepts of the present invention and the prior art should be within the scope of protection defined by the claims.

Claims

1. A synbiotic composition comprising probiotics and dietary fiber, characterized in that: The probiotics are Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) BPB22 three probiotics; the dietary fiber is coix seed soluble dietary fiber; Among them, the preservation number of the Bifidobacterium pseudocatenulatum is CCTCC NO: M 2025538, the preservation number of the Faecalibacterium prausnitzii is CCTCC NO: M 2025537, and the preservation number of the Eubacterium rectale is CCTCC NO: M 20232177.

2. The synbiotic composition according to claim 1, characterized in that The ratio of the probiotics to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale The dosage ratio of BPB22 and high molecular weight coix seed soluble dietary fiber ranged from (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (50-150) g / L.

3. The synbiotic composition according to claim 2, characterized in that The ratio of the probiotics to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum )HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectum ( Eubacterium rectale ) The dosage ratio of BPB22 and high molecular weight coix seed soluble dietary fiber was 5×10 8 CFU / mL: 5×10 8 CFU / mL: 5×10 8 CFU / mL:100g / L.

4. Use of the synbiotic composition according to any one of claims 1 to 3 in the preparation of a medicament for treating insulin resistance.

Images